GCP
TGTX icon

GSA Capital Partners’s TG Therapeutics TGTX Stock Holding History

GSA Capital Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
+18,694
New +$765K 0.06% 491
2026
Q1 		– Sell
-7,417
Closed -$221K – 2152
2025
Q4 		$221K Sell
7,417
-3,478
-32% -$114K 0.02% 1348
2025
Q3 		$394K Buy
+10,895
New +$359K 0.03% 1017
2025
Q2 		– Sell
-5,680
Closed -$224K – 2143
2025
Q1 		$224K Buy
+5,680
New +$191K 0.02% 1340
2024
Q4 		– Sell
-10,987
Closed -$257K – 2029
2024
Q3 		$257K Sell
10,987
-13,465
-55% -$294K 0.02% 1302
2024
Q2 		$435K Buy
+24,452
New +$390K 0.03% 1053
2023
Q4 		– Sell
-22,857
Closed -$191K – 1923
2023
Q3 		$191K Sell
22,857
-48,661
-68% -$678K 0.02% 1293
2023
Q2 		$1.78M Buy
71,518
+38,107
+114% +$984K 0.18% 86
2023
Q1 		$503K Sell
33,411
-98,482
-75% -$1.5M 0.05% 718
2022
Q4 		$1.56M Buy
131,893
+92,427
+234% +$671K 0.19% 57
2022
Q3 		$234K Sell
39,466
-5,815
-13% -$38.1K 0.03% 1109
2022
Q2 		$192K Sell
45,281
-17,903
-28% -$112K 0.03% 1082
2022
Q1 		$601K Buy
63,184
+52,440
+488% +$607K 0.08% 422
2021
Q4 		$204K Buy
+10,744
New +$279K 0.03% 1217
2021
Q1 		– Sell
-6,442
Closed -$335K – 1490
2020
Q4 		$335K Buy
+6,442
New +$218K 0.05% 678
2019
Q4 		– Sell
-61,115
Closed -$343K – 1726
2019
Q3 		$343K Buy
+61,115
New +$426K 0.05% 799

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

GSA Capital Partners's TGTX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in TG Therapeutics (TGTX) in Q2 2026: 18,694 shares worth $1.03M. The stake represents 0.06% of the portfolio and ranks #491 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TGTX as recently as Q4 2025.

GSA Capital Partners first reported a position in TGTX in Q3 2019 and has held it in 16 quarters since. The position peaked at $1.78M in Q2 2023. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • GSA Capital Partners held 18,694 shares of TG Therapeutics worth $1.03M as of Q2 2026.
  • TG Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • TG Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #491 holding.
  • GSA Capital Partners first reported a position in TG Therapeutics in Q3 2019 and has held it in 16 quarters since.
  • GSA Capital Partners's TG Therapeutics position peaked at $1.78M in Q2 2023.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.